Drug intelligence / Profile preview

house dust mite allergen

Development stage
Phase 2
Lead developer
ALK Abelló
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Inhalation, Intranasal
01

Overview

House dust mite (HDM) allergen is a biological extract derived from mites such as *Dermatophagoides pteronyssinus* or *Dermatophagoides farinae*. In clinical research settings, such as those led by the Fraunhofer-Institute of Toxicology and Experimental Medicine, it is utilized as an investigational challenge agent rather than a therapeutic drug. The allergen is typically aerosolized in a controlled Allergen Challenge Chamber (ACC) to induce standardized IgE-mediated allergic responses in sensitized patients. This model is used to study the immunological and clinical skin responses in conditions like atopic dermatitis and allergic rhinitis, facilitating the development of new therapies by providing a reproducible environment for allergen exposure. The specific extract used in the Fraunhofer studies is sourced from ALK-Abello as a lyophilized SQ503 Der p preparation.

Other names
HDM allergenDermatophagoides pteronyssinus allergen extractDer pALK lyophilised SQ503 Der p
02

Targets

HDM-BCR (House dust mite-specific B-cell receptor)TCR (T cell antigen receptor complex)TLR4 (Toll-like receptor 4)Tight junction and cell surface proteins cleaved by Dermatophagoides pteronyssinus allergen 1 (Der p 1)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on house dust mite allergen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on house dust mite allergen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call